SignalSilence siRNA
SignalSilence® TrkA siRNA I #6613
| Item # | Description | List Price | Web Price | QTY | Buy |
|---|
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| H |
Applications Key:
Reactivity Key:
H = Human
Species cross-reactivity is determined by Western blot.
Description
SignalSilence® TrkA siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit TrkA expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Western Blotting
Western blot analysis of extracts from SMS-KCN cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® TrkA siRNA I (+), using TrkA (14G6) Rabbit mAb #2508 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The TrkA (14G6) Rabbit mAb confirms silencing of TrkA expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.
Directions for Use
CST recommends transfection with 100 nM TrkA siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Background
The family of Trk receptor tyrosine kinases consists of TrkA, TrkB and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3. TrkA regulates proliferation and is important for development and maturation of the nervous system (1). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade. Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at this site reflects TrkA kinase activity (2-6). Point mutations, deletions and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA. Many malignancies including breast, colon, prostate and thyroid carcinomas and acute myeloid leukemia have activated TrkA. Expression of TrkA in neuroblastomas is a good prognostic marker because it signals growth arrest and differentiation of cells originating from the neural crest (1).
- Pierotti, M.A. and Greco, A. et al. (2006) Cancer Lett232, 90 - 8.
- Segal, R.A. and Greenberg, M.E. et al. (1996) Annu Rev Neurosci19, 463 - 89.
- Stephens, R.M. et al. (1994) Neuron12, 691 - 705.
- Obermeier, A. et al. (1993) EMBO J12, 933 - 41.
- Obermeier, A. et al. (1994) EMBO J13, 1585 - 90.
- Yao, R. and Cooper, G.M. et al. (1995) Science267, 2003 - 6.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 6201 SignalSilence® Control siRNA (Fluorescein Conjugate)
- 2508 TrkA (14G6) Rabbit mAb
- 2505 TrkA Antibody
- 6568 SignalSilence® Control siRNA (Unconjugated)
This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.
